HIGH-DOSE SEMAGLUTIDE (UP TO 16 MG) IN PEOPLE WITH TYPE 2 DIABETES AND OVERWEIGHT OR OBESITY: A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIA

Descargar Publicación
Modeling potential cost-effectiveness of tirzepatide versus lifestyle modification for patients with overweight and obesity MASLD development: From molecular pathogenesis toward therapeutic strategies